Treatment-resistant depression (TRD) is major depression that has not lifted after at least two antidepressants, each taken at an adequate dose for an adequate time. TMS (transcranial magnetic stimulation) is an FDA-cleared, non-drug option for adults in that situation: magnetic pulses are aimed at a mood-regulating part of the prefrontal cortex, in daily outpatient sessions over several weeks. Roughly one in three people treated for major depressive disorder in the United States does not reach full relief with medication alone. If that describes you, you have not run out of options. This guide explains what treatment resistance means, what the research shows about TMS after antidepressants fail, who qualifies, and what a course looks like. For the wider picture of depression care in the area, see the guide to depression treatment in Boca Raton.
What Is Treatment-Resistant Depression?
The most widely used clinical definition of treatment-resistant depression is a failure to achieve meaningful symptom improvement after at least two separate antidepressant trials, each at an adequate dose for an adequate duration - typically six to eight weeks at a therapeutic dose. This threshold is used by many insurance carriers to establish medical necessity for advanced interventions like TMS. If you have tried two medications and neither produced remission, you meet the definition most clinicians and payers use. Plans differ, though: a Medicare local coverage determination published by Novitas Solutions, for example, requires failure of one or more medication trials (or intolerance), so always check the criteria of your own plan.
Treatment resistance does not mean your depression is untreatable or that something is uniquely wrong with you. It reflects the biological complexity of the condition. The brain's mood-regulating circuitry is not a single switch but a distributed network, and oral medications that travel through the bloodstream and cross the blood-brain barrier reach that circuitry indirectly. For some patients, that indirect route simply does not produce adequate change in the specific cortical regions driving their symptoms.
Why Depression Can Look Treatment-Resistant
Before a diagnosis of treatment resistance is settled, a careful evaluation looks for factors that can make medication appear to fail. Common contributors include:
- Undiagnosed or undertreated co-occurring conditions such as anxiety disorders, ADHD, or chronic pain syndromes
- Thyroid dysfunction or other medical conditions that worsen or mimic depression
- Genetic variations affecting how the body metabolizes specific antidepressants - a field known as pharmacogenomics
- Inadequate prior trials at doses that were too low or durations that were too short to constitute a fair test
- Ongoing psychosocial stressors that medications alone are not designed to resolve
- Active substance use that blunts antidepressant response
A thorough clinical evaluation should examine the full picture before TMS is recommended, including a detailed review of your prior medication history, dosing, duration of each trial, and any medical factors that may be contributing to your treatment resistance.
Why Medications Often Fall Short After Multiple Trials
The landmark STAR*D trial, a large NIMH-funded study published in the New England Journal of Medicine in 2006, gave clinicians and patients critical real-world data on what happens as patients move through successive antidepressant trials. After a first antidepressant trial, roughly one-third of patients achieved remission. With each subsequent trial, cumulative remission rates climbed but the marginal benefit of each new medication diminished. By the third and fourth treatment levels, the likelihood of achieving remission with any additional antidepressant alone fell substantially - to figures some analyses place at approximately 14 percent or lower at those levels. The National Institute of Mental Health describes STAR*D as the largest and longest study of depression treatment ever conducted, and a 2006 NIMH science update on the results was headlined "Odds of Beating Depression Diminish as Additional Treatment Strategies are Needed".
These numbers are not a reason for hopelessness. They are a reason to consider a fundamentally different mechanism of action. TMS bypasses the bloodstream entirely and delivers focused magnetic pulses directly to targeted cortical regions, producing neuronal activation in areas of the brain that are consistently underactive in depression. It works through a completely different biological pathway than any oral antidepressant, which is why patients who have not responded to multiple medications can still respond to TMS.
How TMS Targets the Depressed Brain
The primary target in standard TMS protocols for depression is the left dorsolateral prefrontal cortex, a region of the frontal lobe that governs executive function, emotional regulation, and the initiation of goal-directed behavior. Neuroimaging studies have consistently shown reduced metabolic activity in this region in patients with major depression. High-frequency TMS - typically 10 pulses per second - applied to the left dorsolateral prefrontal cortex increases activity in that area and in connected limbic structures, including the amygdala and the subgenual anterior cingulate cortex, regions known to regulate emotional responsiveness and sustained mood state.
Some protocols add low-frequency stimulation of the right dorsolateral prefrontal cortex at 1 Hz to inhibit a region that research suggests is often overactive in depression, creating a more balanced bilateral effect. Deep TMS systems using the FDA-cleared H-coil technology developed by BrainsWay can reach cortical tissue up to four centimeters below the scalp surface and stimulate a broader cortical network simultaneously, which may be advantageous for patients who have not responded adequately to conventional surface coil protocols.
Theta Burst Stimulation, an accelerated TMS protocol that received FDA clearance for depression, delivers pulses in rapid triplet bursts and can complete a full therapeutic session in approximately three minutes rather than the traditional 19 to 37 minutes. A landmark randomized controlled trial published in The Lancet in 2018 - the THREE-D trial by Blumberger and colleagues - found Theta Burst Stimulation non-inferior to conventional high-frequency TMS in antidepressant efficacy, with a comparable safety profile across more than 400 patients. The shorter session time is a meaningful practical advantage for working adults who cannot take an extended break from their schedule five days a week.
Does TMS Work When Antidepressants Have Failed?
Yes, for many people. The evidence base for TMS in treatment-resistant populations spans more than two decades of controlled trials and real-world clinical data. The O'Reardon et al. multisite randomized controlled trial published in Biological Psychiatry in 2007 - which formed the foundation of the original FDA clearance - enrolled patients who had failed between one and four antidepressant trials. Active TMS produced statistically significant improvements in depression rating scores compared to sham treatment, with strong effects particularly in patients who had failed fewer prior medications. The trial was designed to reflect the real-world treatment-resistant population rather than idealized research subjects with straightforward clinical histories.
In routine clinical practice outside of tightly controlled trials, real-world response rates in treatment-resistant patients typically range from roughly 50 to 60 percent for meaningful symptom improvement and 30 to 35 percent for full remission, based on published clinical audits and multi-site registry studies. These figures are substantially better than what the STAR*D data showed for additional antidepressant trials in similarly resistant patients, though direct head-to-head comparisons are difficult because patient populations differ across study designs. Response is not guaranteed: a minority of patients get little benefit, which is why clinics track symptoms with rating scales during the course.
Durability of benefit is a natural concern for anyone who has experienced depression returning after prior treatments. A large naturalistic follow-up study published in the Journal of Clinical Psychiatry tracked patients who responded to TMS across a clinical practice network over one year. Approximately 62 percent of respondents remained at or near their post-treatment symptom level without any retreatment during the follow-up period. Those who did relapse frequently responded again to a second TMS course - a meaningful clinical advantage over ECT, which carries cumulative cognitive risks that limit retreatability for some patients. For planning after the first course, see the guide to how long TMS therapy lasts and when retreatment is considered. For the most current literature, search PubMed or ask a prospective provider for a summary of recent evidence relevant to your specific situation.
TMS Versus Other Options for Treatment-Resistant Depression
Patients who have not responded to multiple antidepressants are frequently offered augmentation strategies, meaning a second agent is added to the existing antidepressant. Common augmentation choices include lithium, atypical antipsychotic medications such as quetiapine or aripiprazole, buspirone, or thyroid hormone supplementation. Each can be effective for some patients. However, for patients who have already struggled with medication side effects - weight gain, sexual dysfunction, emotional blunting, fatigue, cognitive fog - adding more systemic agents to an already burdensome regimen is often an unwelcome prospect and adherence tends to suffer accordingly.
Electroconvulsive therapy (ECT) remains the most acutely effective treatment available for severe, refractory depression and is genuinely lifesaving in specific clinical situations, particularly when a patient is in immediate danger, refusing food, or unable to maintain basic self-care. ECT requires general anesthesia, carries real cognitive side effects including short-term memory disruption that can persist for weeks to months after a course, and must be administered in a hospital or surgical center with full anesthesia support. For patients who are medically stable and whose depression, though persistent, is not immediately life-threatening, TMS is a reasonable intermediate step to try before considering ECT.
Ketamine and esketamine (FDA-approved as Spravato) produce rapid antidepressant effects, often within hours of the first infusion, making them valuable tools for patients in acute suicidal crisis or those who need rapid relief while a longer-acting treatment takes hold. The durability of ketamine response beyond the initial infusion series varies substantially across patients and remains an active area of investigation. Spravato requires administration in a certified healthcare setting with mandatory post-dose observation. Some patients benefit from using ketamine and TMS sequentially - ketamine for rapid acute stabilization followed by TMS for sustained, durable effect - and this combined approach is being formally evaluated in ongoing research. A fuller side-by-side is in the comparison of TMS therapy versus ketamine infusions.
TMS occupies a distinctive position in the treatment-resistant landscape: it is non-systemic, meaning no drug circulates through your body; non-invasive, meaning no anesthesia, no needles, and no sedation; performed entirely in an outpatient office setting; and covered by many major insurance plans once clinical criteria are met. For a typical patient who has tried several medications without adequate relief and wants to avoid the burden of more aggressive interventions, TMS is generally the logical next step after augmentation strategies have been exhausted or declined.
What a TMS Course Usually Looks Like
The first appointment is typically a comprehensive psychiatric evaluation, not a TMS session. The clinician reviews your full history - prior diagnoses, every medication you have tried at what dose and for how long, any therapy you have received, relevant medical conditions, and your current symptom profile - and discusses whether TMS is clinically appropriate for your situation. If it is, the clinic typically moves on to insurance verification and prior authorization before scheduling the first treatment session.
The National Institute of Mental Health describes a typical TMS course as daily sessions, five days a week, for four to six weeks, with each session lasting about 3 to 40 minutes depending on the protocol; accelerated protocols deliver several sessions in a day and can finish within about a week. Many FDA-cleared protocols for depression are written as 30 to 36 sessions over six to seven weeks. You sit in a reclining chair, fully awake and clothed. A trained technician positions the TMS coil against the left side of your scalp and calibrates the pulse intensity to your individual motor threshold - the minimum field strength needed to produce a visible twitch in your thumb - which is determined at your first treatment session and used to personalize all subsequent sessions.
During treatment you will hear a series of rapid clicking sounds and feel a rhythmic tapping sensation on your scalp. Most patients describe this as mildly uncomfortable during the first few sessions and essentially unremarkable by the second week. You remain alert throughout - many patients read, listen to a podcast, or simply relax in the chair. When the session ends you walk out of the office and can usually drive yourself home or back to work, with no restriction on activities for the rest of the day.
Many clinics conduct formal symptom assessments using validated rating scales at regular intervals throughout the course, often every two weeks. These check-ins allow the clinician to monitor your trajectory and, when appropriate, adjust stimulation parameters or session frequency. After the initial course, a maintenance plan can be worked out with your clinician - some patients benefit from periodic booster sessions every few weeks or months, while others remain symptom-free for a year or longer without additional TMS.
Who Is a Good Candidate for TMS?
TMS therapy for depression is FDA-cleared for adults diagnosed with major depressive disorder who have not achieved satisfactory improvement from prior antidepressant medications. NIMH notes that the FDA also cleared TMS in March 2024 as an add-on treatment for depression in adolescents aged 15 and older, and that it is not approved for children under 15; for younger patients see the guide to TMS therapy for teens and adolescents. Beyond the core diagnostic requirement, good candidates typically share some combination of the following characteristics:
- Have not achieved adequate symptom relief from one or more antidepressant medications at adequate doses for adequate durations
- Have experienced intolerable side effects from antidepressants that limited their ability to continue those medications
- Have medical reasons to minimize systemic medication load, such as complex drug interactions in older adults managing multiple chronic conditions
- Are pregnant or planning to become pregnant and wish to avoid pharmacological treatment during that period; pregnancy is a case for individual medical judgment, so the treating OB should be part of any care decision
- Prefer a non-pharmacological treatment approach and have discussed this preference with a clinician in the context of their specific clinical situation
TMS is not appropriate for patients with ferromagnetic metal implants in or near the skull, including cochlear implants, certain intracranial aneurysm clips, or metal fragments in the brain from prior injury. A personal history of seizure disorder is not an absolute contraindication in all circumstances but requires careful individual evaluation and full clinical disclosure before TMS can proceed. Patients with implanted cardiac devices such as pacemakers or defibrillators should consult with their cardiologist as part of the pre-TMS evaluation process. Common side effects and what to expect are covered in the TMS side effects and safety guide.
Insurance Coverage and Costs in Florida
TMS coverage has expanded substantially over the past decade, and many patients who meet clinical criteria find that their insurance covers TMS therapy. Medicare covers TMS for major depressive disorder under local coverage determinations issued by the regional Medicare Administrative Contractor, so the exact criteria depend on the contractor that serves your state; ask the clinic which policy applies to you. Most major commercial carriers - Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and others - have formal TMS coverage policies in place. The specific clinical criteria each plan applies, particularly the number of prior antidepressant failures required for authorization and the documentation format accepted, differ by plan and are updated periodically. Always verify your current benefits directly with your carrier rather than relying on general descriptions of coverage.
Ask whether the clinic's billing staff conduct a complete benefits verification before the first TMS session, document your prior treatment history in the format your insurer requires, and submit the authorization on your behalf. Authorization timelines vary by insurer and plan, so ask how long the process usually takes and what out-of-pocket cost to expect before treatment begins. Patients without coverage sometimes ask about self-pay pricing; fees for a complete TMS course vary by provider and change over time, so ask the provider directly for current pricing rather than relying on figures found online. A detailed breakdown is in the guide to TMS therapy cost and insurance coverage.
Treatment-Resistant Depression in Boca Raton, Miami and South Florida
Boca Raton sits in southern Palm Beach County, next to Broward and Miami-Dade counties, and people searching for treatment-resistant depression care in Miami or Boca Raton are often choosing among providers in more than one county. Because a standard course means a visit five days a week, distance and appointment times matter as much as the protocol: ask about early-morning and lunch-hour slots, and whether the clinic offers a shorter accelerated or Theta Burst schedule. The evaluation itself should be done by a licensed psychiatrist who reviews your full medication history, whichever county the clinic is in. For a checklist of questions to ask, see how to choose a TMS provider in Boca Raton.
Boca Raton also has a large and growing senior population. Older adults frequently carry a high existing medication burden from multiple chronic medical conditions, and TMS, which introduces no new drug to the body and is not associated with systemic side effects such as weight gain, cardiac effects, or drug interactions, is often considered for exactly that reason. If you are an adult child helping an aging parent who has not responded to antidepressants, a good first step is an evaluation with a licensed psychiatrist, ideally one with experience treating older adults; see also TMS therapy for seniors and older adults.
TMS as Part of a Comprehensive Plan
TMS works best when it is not delivered in isolation. The research on treatment-resistant depression consistently points to better long-term outcomes when biological interventions like TMS are integrated with psychotherapy, lifestyle modification, and treatment of any co-occurring conditions. If you are working with a therapist, ask the TMS provider to keep them informed of your progress during the course. Sleep quality, regular physical exercise, and nutrition each have documented relationships with neuroplasticity and with the likelihood of maintaining improvement over time.
For patients whose treatment-resistant depression is intertwined with substance use - a common and clinically important pairing - ideally both conditions are addressed together by a team with dual-diagnosis experience (see the addiction guide and the overview of dual diagnosis, when mental health and substance use overlap). Active alcohol or substance use significantly reduces TMS response rates and must be addressed as part of any effective plan, not deferred until after the TMS course is complete.
Frequently Asked Questions
How many antidepressants do I need to have tried before qualifying for TMS therapy?
The minimum is typically two adequate antidepressant trials, meaning each medication was taken at a therapeutic dose for at least six to eight weeks without achieving remission. Some plans, including at least one Medicare local coverage determination, require only one failed trial or intolerance, while others require three or four. A provider will review your full medication history and check your eligibility against your specific insurer's current criteria before submitting a prior authorization request.
What is treatment-resistant depression?
Treatment-resistant depression is major depression that has not improved enough after at least two antidepressants taken at adequate doses for an adequate length of time, usually six to eight weeks each. It is a clinical description, not a verdict: other treatments such as augmentation, TMS, esketamine and ECT remain available, and a review for contributing factors such as thyroid problems or substance use is part of a proper evaluation.
Does TMS work after antidepressants fail?
Often it does. The pivotal 2007 trial enrolled patients who had failed one to four antidepressants and found active TMS beat sham treatment, and clinical audits report meaningful improvement in roughly half or more of treatment-resistant patients. Results vary by person, and benefit tends to be larger in people who have failed fewer medications.
Does Medicare or private insurance cover TMS for treatment-resistant depression in Florida?
Medicare and the major private carriers operating in Florida - including Florida Blue, Aetna, Cigna, and UnitedHealthcare - have TMS coverage policies for patients with major depressive disorder who meet clinical criteria. Coverage requirements and prior authorization rules vary by plan and are updated periodically. Verify your benefits directly with your carrier, and ask the clinic to conduct a formal verification before treatment begins.
How soon will I feel a difference from TMS treatment?
Most patients who respond to TMS begin noticing changes between the third and fifth week of treatment, though some report improvements as early as the second week and others do not notice significant improvement until the full course is complete or shortly after. Response patterns vary individually, which is why many clinics conduct formal symptom assessments at regular intervals. If no change is apparent by week four or five, the clinician may discuss whether protocol adjustments might improve your trajectory.
Can I continue taking my antidepressant medication during TMS?
In most cases, yes. Many patients undergo TMS while continuing a current antidepressant, and some evidence suggests this combination produces better outcomes than TMS alone in certain patients. Your prescribing psychiatrist and the TMS clinician will coordinate to determine whether any medication adjustments make sense before, during, or after your TMS course. Never stop or change a medication without guidance from your prescriber.
Is TMS therapy painful or uncomfortable?
TMS is not painful for most patients, though the tapping sensation on the scalp can be uncomfortable during the first few sessions while the clinician calibrates intensity to your motor threshold. NIMH lists discomfort at the site, scalp or facial tingling, mild headache and brief lightheadedness among common effects; seizures are possible but considered low risk. Discomfort usually diminishes after the first week, and there is no sedation, no anesthesia, and no recovery time.
What are my options if TMS does not produce adequate relief?
A subset of treatment-resistant patients do not respond to an initial TMS course. The clinical conversation then shifts to whether protocol adjustments - such as targeting a different cortical region, using a deep TMS coil, or switching to an accelerated Theta Burst protocol - might produce a different result. Further options include ketamine or esketamine therapy, ECT for severe or immediately dangerous presentations, MAOI antidepressants, or enrollment in a clinical trial. A good provider works with you to identify a viable next step rather than leaving you without a plan.
Where to Go From Here
If antidepressants have not given you sustained relief, the next step is a conversation with a licensed psychiatrist about whether TMS fits your history. Bring a list of every medication you have tried, with doses and dates, and ask about coverage and prior authorization up front. For related reading, see the TMS therapy explained guide, and the guides above on cost, side effects and safety. If you have a question about this guide itself, you can ask a question.
